The strong correlation between NAFLD and metabolic disorders, such as obesity and T2DM, suggests that targeting the GLP-1 may be a promising therapeutic strategy for NAFLD. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.